NasdaqGM - Nasdaq Real Time Price USD

Avidity Biosciences, Inc. (RNA)

26.35

+0.09

+(0.34%)

As of 1:43:57 PM EDT. Market Open.

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference:

PR Newswire yesterday

RNA
+0.34%
Trump’s FDA Sends a Bullish Signal to Biotech

A vow by the agency’s new commissioner, Marty Makary, to support innovation might ease fears stoked by Health and Human Services Secretary Robert F. Kennedy Jr.

The Wall Street Journal 15 days ago

MFG

MZHOF

RGNX
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Investor's Business Daily 15 days ago

DYN

RNA
+0.34%

SRPT
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 263,000 shares of its common stock and 131,450 restricted stock units ("RSUs") to thirty-three (33) new non-executive employees under the Avid

PR Newswire 15 days ago

RNA
+0.34%
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation (ODD) to delpacibart etedesiran (del-desiran) for the treatment of myotonic dystrophy type 1 (DM1), an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and of

PR Newswire 29 days ago

RNA
+0.34%
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against other unstoppable stocks that could double your money. Generating significant returns and multiplying their money in the stock market remains a primary goal […]

Insider Monkey last month

RNA
+0.34%
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks last month

RNA
+0.34%

MIRM
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks last month

GLPG

GLPGF

PTCT
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the completion of enrollment in the biomarker cohort in the Phase 1/2 FORTITUDE™ clinical trial of delpacibart braxlosiran (del-brax) in people living with facioscapulohumeral muscular dystrophy (FSHD). A total of 51 participants were enrolled in the FORTITUDE biomarker cohort.

PR Newswire last month

RNA
+0.34%
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced positive del-zota topline data from the Phase 1/2 EXPLORE44® trial in people living with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) demonstrating consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase as well as favorable safety and tolerab

PR Newswire last month

RNA
+0.34%
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and two poster presentations at the 2025 MDA Clinical & Scientific Conference (MDA) in Dallas, Texas, being held March 16-19, 2025 and will host an investor and analyst webcast event on March 17, 2025.

PR Newswire last month

RNA
+0.34%
Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Avidity Biosciences ( NASDAQ:RNA ) Full Year 2024 Results Key Financial Results Revenue: US$10.9m (up 14% from FY...

Simply Wall St. 2 months ago

RNA
+0.34%
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent need for more approved treatments for many of these conditions in support of Rare Disease Day®.

PR Newswire 2 months ago

RNA
+0.34%
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

Avidity Biosciences (RNA) delivered earnings and revenue surprises of 4.76% and 29.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

RNA
+0.34%
Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during each of the following investor conferences:

PR Newswire 2 months ago

RNA
+0.34%
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

RNA
+0.34%
Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech Stocks While 2024 was a “challenging” year for biotech stocks, […]

Insider Monkey 3 months ago

RNA
+0.34%
Avidity Biosciences Plans to Submit First Biologics License Application This Year

Avidity Biosciences (RNA) said Wednesday it plans to file a biologics license application for delpac

PREMIUM
MT Newswires 3 months ago

RNA
+0.34%
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its progress and planning for a transformational year in 2025. These major anticipated milestones include executing on three potentially registrational programs, filing a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for people living with Duchenne muscular dystrophy mutations a

PR Newswire 3 months ago

RNA
+0.34%
Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?

We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against the other multibagger stocks. The US equities continued their upward movement in 2024 and fueled the S&P 500 to record highs. Much of […]

Insider Monkey 4 months ago

RNA
+0.34%

^GSPC

AMP

Performance Overview

Return	RNA	S&P 500 (^GSPC)
YTD	-9.39%	-4.44%
1-Year	+3.78%	+8.35%
3-Year	+94.04%	+36.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avidity Biosciences, Inc. (RNA)

Avidity Biosciences to Participate in Upcoming Investor Conference

Trump’s FDA Sends a Bullish Signal to Biotech

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Biotech stocks slide as Marks resignation seen being negative for sector

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

Avidity Biosciences to Participate in Upcoming Investor Conferences

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential

Avidity Biosciences Plans to Submit First Biologics License Application This Year

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?

Performance Overview